2- methyl- 6- (3- (2- phenyloxazol- 4- ylmethoxy)propoxymethyl)benzoic acid

cardioprotective agent; structure in first source

Also Known As:

AVE 8134; AVE-8134; AVE8134

Networked: 3 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzoates: 426
        2-methyl-6-(3-(2-phenyloxazol-4-ylmethoxy)propoxymethyl)benzoic acid: 3
- Carboxylic Acids: 973
  - Carbocyclic Acids
    - Benzoates: 426
      - 2-methyl-6-(3-(2-phenyloxazol-4-ylmethoxy)propoxymethyl)benzoic acid: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - 2-methyl-6-(3-(2-phenyloxazol-4-ylmethoxy)propoxymethyl)benzoic acid: 3

Experts

1.	Falk, Eugen: 2 articles (01/2012 - 07/2009)
2.	Linz, Wolfgang: 2 articles (01/2012 - 07/2009)
3.	Rütten, Hartmut: 2 articles (01/2012 - 07/2009)
4.	Chen, Chen: 1 article (12/2019)
5.	Dai, Meiyan: 1 article (12/2019)
6.	Li, Huihui: 1 article (12/2019)
7.	Wang, Daowen: 1 article (12/2019)
8.	Wang, Wei: 1 article (12/2019)
9.	Wu, Lujin: 1 article (12/2019)
10.	Glien, Maike: 1 article (01/2012)

Related Diseases

1.	Insulin Resistance 01/01/2012 - "In female ZDF rats, AVE8134 (3-30 mg·kg(-1)·d(-1) for 2 weeks) improved insulin-sensitivity index. "
2.	Heart Failure 07/01/2009 - "To investigate the efficacy of the peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, AVE8134, in cellular and experimental models of cardiac dysfunction and heart failure. " 07/01/2009 - "The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats."
3.	Cardiomegaly (Heart Hypertrophy) 07/01/2009 - "In DOCA-salt sensitive rats, efficacy of AVE8134 on cardiac hypertrophy and fibrosis was investigated. "
4.	Fibrosis (Cirrhosis) 07/01/2009 - "In post-MI rats, AVE8134 dose-dependently improved cardiac output, myocardial contractility and relaxation and reduced lung and left ventricular weight and fibrosis. " 07/01/2009 - "The PPARalpha agonist AVE8134 prevents post-MI myocardial hypertrophy, fibrosis and cardiac dysfunction. " 07/01/2009 - "In DOCA rats, AVE8134 prevented development of high blood pressure, myocardial hypertrophy and cardiac fibrosis, and ameliorated endothelial dysfunction. " 07/01/2009 - "In DOCA-salt sensitive rats, efficacy of AVE8134 on cardiac hypertrophy and fibrosis was investigated. "
5.	Neoplasms (Cancer) 12/02/2019 - "Considering their safety and efficacy, the novel PPARα ligand, AVE8134, is a potentially ideal anti-angiogenesis drug for cancer treatment when jointly applied with the COX inhibitor indomethacin."

Related Drugs and Biologics

1.	Desoxycorticosterone Acetate (DOCA)
2.	PPAR alpha
3.	Salts
4.	Cyclooxygenase Inhibitors
5.	Phenylephrine (Neo-Synephrine)
6.	Nitric Oxide (Nitrogen Monoxide)
7.	Ligands
8.	Indomethacin (Indometacin)
9.	Rosiglitazone (Avandia)
10.	oxidized low density lipoprotein

Related Therapies and Procedures

1.	Therapeutics